Results 81 to 90 of about 44,923 (207)
British Journal of Pharmacology, EarlyView.Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen +12 more
wiley +1 more source
Cancer Treatment and Research CommunicationsPurpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment
Maria Ignez Freitas Melro Braghiroli +13 more
doaj +1 more source
Cancer Science, EarlyView.This study aimed to determine whether personalized selection of effective drugs for SMARCB1/INI1‐deficient tumors is feasible using in vitro drug sensitivity profiling. Drug sensitivity was assessed using a short‐term collagen gel–embedded three‐dimensional drug sensitivity test (3D‐DST) in tumors derived from SMARCB1/INI1‐deficient tumor cell line ...
Hiroaki Goto +12 more
wiley +1 more source
Cancer Science, EarlyView.Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe +5 more
wiley +1 more source
Rifaximin alleviates irinotecan-induced diarrhea in mice model
Annals of MedicineBackground Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Chengyi Huang +9 more
doaj +1 more source
New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer
Cancer Science, EarlyView.Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi +2 more
wiley +1 more source
Lysine l‐Lactylation: Bridging Metabolism, Chromatin and Disease
Cell Proliferation, EarlyView.Enzymatic regulation of KL‐la. The enzymatic regulation of KL‐la involves two distinct pathways for L‐lactate accumulation: intracellular production through glycolysis‐derived pyruvate conversion by lactate dehydrogenase (LDH) or direct cellular uptake via monocarboxylate transporters (MCTs). These L‐lactate pools fuel two distinct lactylation pathways—
Anoosha Malik +10 more
wiley +1 more source
Histopathology, EarlyView.TAC/SARIFA, defined by direct tumour–adipocyte contact at the invasion front, represents a reproducible, biologically meaningful H&E biomarker with consistent adverse prognostic associations in CRC. Aims Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E ...
Nic G Reitsam +3 more
wiley +1 more source
Genomic Medicine Sweden: Advancing precision medicine at the national level
Journal of Internal Medicine, EarlyView.Abstract High‐throughput sequencing has transformed clinical diagnostics of rare diseases (RD), cancer and infectious diseases by enabling the identification of disease‐causing genetic alterations and facilitating individualised treatment and care.
Anders Edsjö +58 more
wiley +1 more source